Breakfast News: A Conversation With Ionis CEO

Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (NYSEMKT: XBI) is up 39% year to date -- beating tech and running even with energy. But it's been volatile, too. Moderna's (NASDAQ: MRNA) 177% single-day pop just pulled the whole sector sharply higher. Yet as recently as April, pharma tariffs, most-favored-nation pricing, and regulatory upheaval had biotech in the red.Ionis Pharmaceuticals (NASDAQ: IONS) knows volatility. A catalyst-rich year drove the stock to an all-time high in February. Then a surprising clinical failure sent it down more than 30% in two sessions. With four months left in the year, Ionis still has a lot ahead:We sat down with CEO Brett Monia to talk through 2026 and beyond -- and why Ionis is thinking well past its near-term milestones.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool